Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

7.1%

1 terminated out of 14 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

29%

4 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results75% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (4)
P 2 (3)
P 3 (2)
P 4 (2)

Trial Status

Recruiting5
Completed3
Unknown2
Active Not Recruiting2
Terminated1
Withdrawn1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06691113Phase 2Active Not RecruitingPrimary

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06069310Active Not Recruiting

Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma

NCT06850805Phase 3RecruitingPrimary

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT07198607Not ApplicableCompletedPrimary

Pistacia Lentiscus Oil Nasal Drops for Preventing Recurrence of Chronic Rhinosinusitis

NCT06013241Phase 2CompletedPrimary

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT07184684Phase 2RecruitingPrimary

Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS).

NCT06398873Recruiting

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

NCT06118554Not ApplicableRecruiting

3D Printing to Improve Nasal Irrigation Outcome

NCT04678856Phase 3CompletedPrimary

Dupilumab in CRSsNP

NCT05642806Phase 4Recruiting

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

NCT05843019UnknownPrimary

Adherence in Global Airways - Steroid Intake and Effects on Chronic Rhinosinosinutis

NCT05553951Not ApplicableUnknownPrimary

Adherence in Global Airways

NCT04158596Not ApplicableWithdrawnPrimary

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT01676415Phase 4TerminatedPrimary

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Showing all 14 trials

Research Network

Activity Timeline